Loading
Block the survival signal and remove the death shield at the same time, for about a year, then stop and stay in remission for years.
CAPTIVATE and GLOW (ibrutinib), AMPLIFY (acalabrutinib; FDA approved February 2026), SEQUOIA arm D (zanubrutinib), and CELESTIAL (sonrotoclax + zanubrutinib) all show high uMRD and durable PFS after 12-15 months of therapy. Fixed duration reduces cumulative toxicity and cost versus indefinite BTK inhibition.
Shares Sonrotoclax, Zanubrutinib, Acalabrutinib, Chronic lymphocytic leukaemia, first treatment.
Shares SEQUOIA, Zanubrutinib, Acalabrutinib, BTK (Bruton tyrosine kinase).
Shares CELESTIAL-TNCLL, CAPTIVATE, Sonrotoclax, Zanubrutinib.
Shares SEQUOIA, Zanubrutinib, Chronic lymphocytic leukaemia, first treatment, Venetoclax.
Shares Zanubrutinib, Acalabrutinib, Chronic lymphocytic leukaemia, first treatment, Ibrutinib.
Shares Acalabrutinib, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia, first treatment, Ibrutinib.
Shares Zanubrutinib, Acalabrutinib, Chronic lymphocytic leukaemia, first treatment, Ibrutinib.
Shares Zanubrutinib, Acalabrutinib, BTK (Bruton tyrosine kinase), Ibrutinib.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/